A systematic review examining skeletal effects of GLP-1 receptor agonist therapy, a class that includes exenatide, was published on October 23, 2026. The publication, titled "Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review," appeared in Archives of Osteoporosis.
The review focuses on adults with overweight or obesity treated with GLP-1 receptor agonist therapy. Exenatide is approved and falls within this drug class under review. The publication is identified by PubMed ID 42920024.
No specific findings, conclusions, or data points from the review are included in this report. The scope of the publication, as stated, pertains to skeletal effects associated with this therapy class in the specified patient population. Readers interested in the full scope of the systematic review's methodology and conclusions should consult the original publication directly through the source listed.
This brief reports only the existence and basic details of this publication as recorded. For additional background on exenatide, including its regulatory status and general profile, readers can refer to the compound overview.